Biologic response modifiers as adjuncts to other therapeutic modalities.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D001500:BCG Vaccine / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000628:therapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D007938:Leukemia / Q000628:therapy; D007978:Levamisole / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008545:Melanoma / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D011063:Poly A-U / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000628:therapy; D014750:Vincristine / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D011063:Poly A-U; D007978:Levamisole; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007372:Interferons; D011241:Prednisone